Corindus Vascular Robotics, whose CorPath GRX has FDA approval for percutaneous coronary and vascular procedures, will be acquired by Siemens Healthineers.
6 robotics applications demonstrating new tech, markets
As robots expand beyond manufacturing, what should developers know about new applications? Here are six examples of robotics needs.
Corindus submits CorPath GRX to FDA for robotic neurovascular interventions
Corindus Vascular Robotics this week said it applied to the U.S. Food and Drug Administration for premarket clearance to use its CorPath GRX robotic surgical platform in neurovascular interventions. The Waltham, Mass.-based company has already received FDA clearance for percutaneous coronary interventions (PCI), which it won in 2016, and for peripheral vascular interventions (PVI), which it won last…
Corindus CorPath GRX surgical robot receives clearance in Japan
Corindus Vascular Robotics has won clearance from Japan’s Pharmaceutical and Medical Device Agency for its CorPath GRX robotic surgical device. The CorPath GRX vascular robotics platform is designed to assist cardiologists in performing percutaneous coronary interventions (PCI) procedures, including angioplasty and stent placement. Japan is one of the largest markets in the world for PCIs, according to…
Corindus raises $25M to commercialize CorPath GRX surgical robot
Corindus Vascular Robotics inked a private placement deal worth $25 million through the offering of newly-designated Series A convertible preferred stock, with funds slated to support global commercialization of its CorPath GRX robotic surgical system. The Waltham, Mass.-based company will issue shares of Series A convertible preferred stock convertible into 20 million shares of common stock…
FDA clears software for Corindus CorPath GRX surgical robot
Corindus Vascular Robotics has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the first automated robotic movement designed for its CorPath GRX platform. Called “Rotate on Retract” (RoR), the proprietary software feature is the first automated robotic movement in the technIQ Series for the CorPath GRX platform. It allows the operator…
Corindus joins with Mayo Clinic in study of tele-robotic stenting
Corindus Vascular Robotics (OTC:CVRS) said today it is working with the Mayo Clinic to launch preclinical studies exploring the use of telestenting, a robotic treatment for percutaneous coronary interventions which can be operated by physicians in remote locations. The Waltham, Mass.-based surgical robotics company said that there is a global shortage of PCI-capable operators, and that telestenting…
Corindus touts 1st Corpath GRX system installation outside the US
Corindus Vascular Robotics (OTC:CVRS) today touted the first commercial installation of its CorPath GRx robotic surgical system outside of the US. The CorPath GRX platform, a robot-assisted system for percutaneous coronary interventions such as stenting, was purchased and installed at the Ahmedabad, India’s Apex Heart Institute, the Waltham, Mass.-based company said. Corindus said that it will…
Corindus Vascular Robotics to test-drive HeartFlow’s 3D cardiac imaging tech
Corindus Vascular Robotics (OTC:CVRS), a Massachusetts-based surgical robotics company, plans to utilize technology that creates 3D images of arteries for evaluating patients. Company officials said they’d employ California-based HeartFlow’s FFRct Analysis in a case series of robotic-assisted percutaneous coronary interventions to evaluate the technology’s role in clinical decision support. The testing will be done at hospitals…